Related references
Note: Only part of the references are listed.Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus
Manfred Kunz et al.
EXPERIMENTAL DERMATOLOGY (2015)
Photosensitivity, Apoptosis, and Cytokines in the Pathogenesis of Lupus Erythematosus: a Critical Review
Annegret Kuhn et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2014)
Role of DNA/RNA sensors and contribution to autoimmunity
Siobhan Smith et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Jakpot! New small molecules in autoimmune and inflammatory diseases
Kamran Ghoreschi et al.
EXPERIMENTAL DERMATOLOGY (2014)
Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling
Magdalena Kistowska et al.
EXPERIMENTAL DERMATOLOGY (2014)
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Thorsten Hornung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling
Alexandros P. Grammatikos et al.
PLOS ONE (2013)
Targeted Tumor Necrosis Factor Receptor I Preligand Assembly Domain Improves Skin Lesions in MRL/lpr Mice
Guo-Min Deng et al.
ARTHRITIS AND RHEUMATISM (2010)
The SYK tyrosine kinase: a crucial player in diverse biological functions
Attila Mocsai et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus
Joerg Wenzel et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2009)
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation
Laura Carsetti et al.
CELLULAR SIGNALLING (2009)
An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in interface dermatitis''
Joerg Wenzel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus
J Wenzel et al.
JOURNAL OF PATHOLOGY (2005)
Significance analysis of microarrays applied to the ionizing radiation response
VG Tusher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)